Group a streptococcal diseases and their global burden

Anna Ralph, Jonathan Carapetis

    Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

    Abstract

    Group A streptococcus (GAS) or Streptococcus pyogenes has been recognised as an important human pathogen since early days of modern microbiology, and it remains among the top ten causes of mortality from an infectious disease. Clinical manifestations attributable to this organism are perhaps the most diverse of any single human pathogen. These encompass invasive GAS infections, with high mortality rates despite effective antimicrobials, toxin-mediated diseases including scarlet fever and streptococcal toxic shock syndrome, the autoimmune sequelae of rheumatic fever and glomerulonephritis with potential for long-term disability, and nuisance manifestations of superficial skin and pharyngeal infection, which continue to consume a sizable proportion of healthcare resources. Although an historical perspective indicates major overall reductions in GAS infection rates in the modern era, chiefly as a result of widespread improvements in socioeconomic circumstances, this pathogen remains as a leading infectious cause of global morbidity and mortality. More than 18 million people globally are estimated to suffer from serious GAS disease. This burden disproportionally affects least affluent populations, and is a major cause of illness and death among children and young adults, including pregnant women, in low-resource settings. We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease attributable to GAS. The lack of systematic reporting makes accurate estimation of rates difficult. This highlights the need to support improved surveillance and epidemiological research in low-resource settings, in order to enable better assessment of national and global disease burdens, target control strategies appropriately and assess the success of control interventions. 

    Original languageEnglish
    Title of host publicationHost-Pathogen Interactions in Streptococcal Diseases
    EditorsG. Singh Chhatwal
    Place of PublicationHeidelberg New York Dordrecht London
    PublisherSpringer
    Chapter1
    Pages1-27
    Number of pages27
    ISBN (Electronic)978-3-642-36340-5
    ISBN (Print)978-3-642-36339-9
    DOIs
    Publication statusPublished - 2013

    Publication series

    NameCurrent Topics in Microbiology and Immunology
    Volume368
    ISSN (Print)0070-217X

    Fingerprint

    Streptococcus
    Mortality
    Infection
    Scarlet Fever
    Skin Manifestations
    Rheumatic Fever
    Streptococcus pyogenes
    Septic Shock
    Glomerulonephritis
    Microbiology
    Communicable Diseases
    Global Burden of Disease
    Pregnant Women
    Young Adult
    Cause of Death
    Morbidity
    Delivery of Health Care
    Research
    Population

    Cite this

    Ralph, A., & Carapetis, J. (2013). Group a streptococcal diseases and their global burden. In G. S. Chhatwal (Ed.), Host-Pathogen Interactions in Streptococcal Diseases (pp. 1-27). (Current Topics in Microbiology and Immunology; Vol. 368). Heidelberg New York Dordrecht London: Springer. https://doi.org/10.1007/82_2012_280
    Ralph, Anna ; Carapetis, Jonathan. / Group a streptococcal diseases and their global burden. Host-Pathogen Interactions in Streptococcal Diseases. editor / G. Singh Chhatwal. Heidelberg New York Dordrecht London : Springer, 2013. pp. 1-27 (Current Topics in Microbiology and Immunology).
    @inbook{e32c61c6f160479794dadf66a1d8be34,
    title = "Group a streptococcal diseases and their global burden",
    abstract = "Group A streptococcus (GAS) or Streptococcus pyogenes has been recognised as an important human pathogen since early days of modern microbiology, and it remains among the top ten causes of mortality from an infectious disease. Clinical manifestations attributable to this organism are perhaps the most diverse of any single human pathogen. These encompass invasive GAS infections, with high mortality rates despite effective antimicrobials, toxin-mediated diseases including scarlet fever and streptococcal toxic shock syndrome, the autoimmune sequelae of rheumatic fever and glomerulonephritis with potential for long-term disability, and nuisance manifestations of superficial skin and pharyngeal infection, which continue to consume a sizable proportion of healthcare resources. Although an historical perspective indicates major overall reductions in GAS infection rates in the modern era, chiefly as a result of widespread improvements in socioeconomic circumstances, this pathogen remains as a leading infectious cause of global morbidity and mortality. More than 18 million people globally are estimated to suffer from serious GAS disease. This burden disproportionally affects least affluent populations, and is a major cause of illness and death among children and young adults, including pregnant women, in low-resource settings. We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease attributable to GAS. The lack of systematic reporting makes accurate estimation of rates difficult. This highlights the need to support improved surveillance and epidemiological research in low-resource settings, in order to enable better assessment of national and global disease burdens, target control strategies appropriately and assess the success of control interventions. ",
    keywords = "azithromycin, benzathine penicillin, beta lactam, clindamycin, erythromycin, lincosamide derivative, penicillin derivative, rifampicin, antibiotic resistance, article, bacterial colonization, bacterium culture, disease course, disease transmission, epidemic, geographic distribution, glomerulonephritis, group A streptococcal infection, human, incidence, infection control, microbial diversity, morbidity, mortality, nonhuman, population distribution, prevalence, priority journal, pyoderma, rheumatic fever, rheumatic heart disease, scarlet fever, skin infection, streptococcal pharyngitis, Streptococcus pyogenes, vaccination",
    author = "Anna Ralph and Jonathan Carapetis",
    year = "2013",
    doi = "10.1007/82_2012_280",
    language = "English",
    isbn = "978-3-642-36339-9",
    series = "Current Topics in Microbiology and Immunology",
    publisher = "Springer",
    pages = "1--27",
    editor = "Chhatwal, {G. Singh}",
    booktitle = "Host-Pathogen Interactions in Streptococcal Diseases",
    address = "Switzerland",

    }

    Ralph, A & Carapetis, J 2013, Group a streptococcal diseases and their global burden. in GS Chhatwal (ed.), Host-Pathogen Interactions in Streptococcal Diseases. Current Topics in Microbiology and Immunology, vol. 368, Springer, Heidelberg New York Dordrecht London, pp. 1-27. https://doi.org/10.1007/82_2012_280

    Group a streptococcal diseases and their global burden. / Ralph, Anna; Carapetis, Jonathan.

    Host-Pathogen Interactions in Streptococcal Diseases. ed. / G. Singh Chhatwal. Heidelberg New York Dordrecht London : Springer, 2013. p. 1-27 (Current Topics in Microbiology and Immunology; Vol. 368).

    Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

    TY - CHAP

    T1 - Group a streptococcal diseases and their global burden

    AU - Ralph, Anna

    AU - Carapetis, Jonathan

    PY - 2013

    Y1 - 2013

    N2 - Group A streptococcus (GAS) or Streptococcus pyogenes has been recognised as an important human pathogen since early days of modern microbiology, and it remains among the top ten causes of mortality from an infectious disease. Clinical manifestations attributable to this organism are perhaps the most diverse of any single human pathogen. These encompass invasive GAS infections, with high mortality rates despite effective antimicrobials, toxin-mediated diseases including scarlet fever and streptococcal toxic shock syndrome, the autoimmune sequelae of rheumatic fever and glomerulonephritis with potential for long-term disability, and nuisance manifestations of superficial skin and pharyngeal infection, which continue to consume a sizable proportion of healthcare resources. Although an historical perspective indicates major overall reductions in GAS infection rates in the modern era, chiefly as a result of widespread improvements in socioeconomic circumstances, this pathogen remains as a leading infectious cause of global morbidity and mortality. More than 18 million people globally are estimated to suffer from serious GAS disease. This burden disproportionally affects least affluent populations, and is a major cause of illness and death among children and young adults, including pregnant women, in low-resource settings. We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease attributable to GAS. The lack of systematic reporting makes accurate estimation of rates difficult. This highlights the need to support improved surveillance and epidemiological research in low-resource settings, in order to enable better assessment of national and global disease burdens, target control strategies appropriately and assess the success of control interventions. 

    AB - Group A streptococcus (GAS) or Streptococcus pyogenes has been recognised as an important human pathogen since early days of modern microbiology, and it remains among the top ten causes of mortality from an infectious disease. Clinical manifestations attributable to this organism are perhaps the most diverse of any single human pathogen. These encompass invasive GAS infections, with high mortality rates despite effective antimicrobials, toxin-mediated diseases including scarlet fever and streptococcal toxic shock syndrome, the autoimmune sequelae of rheumatic fever and glomerulonephritis with potential for long-term disability, and nuisance manifestations of superficial skin and pharyngeal infection, which continue to consume a sizable proportion of healthcare resources. Although an historical perspective indicates major overall reductions in GAS infection rates in the modern era, chiefly as a result of widespread improvements in socioeconomic circumstances, this pathogen remains as a leading infectious cause of global morbidity and mortality. More than 18 million people globally are estimated to suffer from serious GAS disease. This burden disproportionally affects least affluent populations, and is a major cause of illness and death among children and young adults, including pregnant women, in low-resource settings. We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease attributable to GAS. The lack of systematic reporting makes accurate estimation of rates difficult. This highlights the need to support improved surveillance and epidemiological research in low-resource settings, in order to enable better assessment of national and global disease burdens, target control strategies appropriately and assess the success of control interventions. 

    KW - azithromycin

    KW - benzathine penicillin

    KW - beta lactam

    KW - clindamycin

    KW - erythromycin

    KW - lincosamide derivative

    KW - penicillin derivative

    KW - rifampicin

    KW - antibiotic resistance

    KW - article

    KW - bacterial colonization

    KW - bacterium culture

    KW - disease course

    KW - disease transmission

    KW - epidemic

    KW - geographic distribution

    KW - glomerulonephritis

    KW - group A streptococcal infection

    KW - human

    KW - incidence

    KW - infection control

    KW - microbial diversity

    KW - morbidity

    KW - mortality

    KW - nonhuman

    KW - population distribution

    KW - prevalence

    KW - priority journal

    KW - pyoderma

    KW - rheumatic fever

    KW - rheumatic heart disease

    KW - scarlet fever

    KW - skin infection

    KW - streptococcal pharyngitis

    KW - Streptococcus pyogenes

    KW - vaccination

    UR - http://www.scopus.com/inward/record.url?scp=84892922350&partnerID=8YFLogxK

    U2 - 10.1007/82_2012_280

    DO - 10.1007/82_2012_280

    M3 - Chapter

    SN - 978-3-642-36339-9

    T3 - Current Topics in Microbiology and Immunology

    SP - 1

    EP - 27

    BT - Host-Pathogen Interactions in Streptococcal Diseases

    A2 - Chhatwal, G. Singh

    PB - Springer

    CY - Heidelberg New York Dordrecht London

    ER -

    Ralph A, Carapetis J. Group a streptococcal diseases and their global burden. In Chhatwal GS, editor, Host-Pathogen Interactions in Streptococcal Diseases. Heidelberg New York Dordrecht London: Springer. 2013. p. 1-27. (Current Topics in Microbiology and Immunology). https://doi.org/10.1007/82_2012_280